Analysis of Short-term (Operating) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Vertex Pharmaceuticals Inc., short-term (operating) activity ratios
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of short-term operating activity ratios reveals several notable trends over the five-year period. Generally, a decline in efficiency is observed across several key metrics, particularly concerning inventory management, while receivables management demonstrates more stability. Payables management remains relatively consistent, and the cash conversion cycle has lengthened considerably.
- Inventory Management
- Inventory turnover decreased consistently from 2.56 in 2021 to 0.98 in 2025. This indicates a growing inefficiency in converting inventory into sales. Correspondingly, the average inventory processing period lengthened substantially, increasing from 143 days in 2021 to 373 days in 2025. This suggests inventory is being held for a significantly longer duration, potentially due to slowing sales, overstocking, or obsolescence.
- Receivables Management
- Receivables turnover exhibited relative stability between 2021 and 2024, fluctuating between 6.19 and 6.85. A slight decrease to 5.85 is noted in 2025. The average receivable collection period remained relatively consistent, ranging from 53 to 62 days over the period. These figures suggest consistent efficiency in collecting receivables, although the 2025 value warrants monitoring.
- Payables Management
- Payables turnover showed a decrease from 4.64 in 2021 to 3.58 in 2025, indicating a slower rate of paying suppliers. The average payables payment period increased from 79 days in 2021 to 102 days in 2025, suggesting the company is taking longer to settle its obligations. While this could indicate improved cash management, it should be evaluated in conjunction with other metrics.
- Working Capital & Operating Cycle
- Working capital turnover initially decreased from 1.02 in 2021 to 0.85 in 2022, then increased significantly to 1.83 in 2024 before decreasing slightly to 1.64 in 2025. The operating cycle lengthened considerably, rising from 198 days in 2021 to 435 days in 2025. This expansion is primarily driven by the increasing inventory processing period.
- Cash Conversion Cycle
- The cash conversion cycle demonstrated a consistent upward trend, increasing from 119 days in 2021 to 333 days in 2025. This indicates a longer period between paying for inventory and receiving cash from sales, potentially tying up significant working capital. The lengthening cycle is attributable to the combined effects of the increasing inventory processing period and, to a lesser extent, the increasing payables payment period.
In summary, the observed trends suggest a deterioration in overall operating efficiency, particularly concerning inventory management. The lengthening cash conversion cycle is a key area of concern and warrants further investigation to identify the underlying causes and potential mitigation strategies.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Inventory Turnover
Vertex Pharmaceuticals Inc., inventory turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cost of sales | 1,651,300) | 1,530,500) | 1,262,200) | 1,080,300) | 904,200) | |
| Inventories | 1,686,800) | 1,205,400) | 738,800) | 460,600) | 353,100) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 0.98 | 1.27 | 1.71 | 2.35 | 2.56 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | |
| Amgen Inc. | 1.93 | 1.84 | 0.89 | 1.30 | 1.58 | |
| Bristol-Myers Squibb Co. | 5.18 | 5.46 | 4.02 | 4.33 | 4.74 | |
| Danaher Corp. | 4.04 | 4.15 | 3.80 | 4.03 | 4.16 | |
| Eli Lilly & Co. | 0.80 | 1.11 | 1.23 | 1.54 | 1.88 | |
| Gilead Sciences Inc. | 3.51 | 3.66 | 3.64 | 3.75 | 4.08 | |
| Johnson & Johnson | 2.13 | 2.21 | 2.37 | 2.49 | 2.87 | |
| Merck & Co. Inc. | 2.46 | 2.49 | 2.54 | 2.95 | 2.29 | |
| Pfizer Inc. | 1.51 | 1.65 | 2.45 | 3.82 | 3.40 | |
| Regeneron Pharmaceuticals Inc. | 0.66 | 0.64 | 0.70 | 0.65 | 1.25 | |
| Thermo Fisher Scientific Inc. | 4.85 | 5.06 | 5.06 | 4.60 | 3.88 | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.23 | 2.46 | 2.55 | 3.06 | 3.11 | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.55 | 7.56 | 7.36 | 7.85 | 7.90 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of sales ÷ Inventories
= 1,651,300 ÷ 1,686,800 = 0.98
2 Click competitor name to see calculations.
A consistent decline in inventory turnover is observed over the five-year period. This indicates a lengthening of the time it takes for the company to sell its inventory. Simultaneously, both cost of sales and inventories demonstrate increasing values year over year, though the rate of increase differs.
- Inventory Turnover
- The inventory turnover ratio decreased from 2.56 in 2021 to 0.98 in 2025. This represents a substantial reduction in efficiency regarding inventory management. The most significant decrease occurred between 2022 and 2023, falling from 2.35 to 1.71, and continued to decline steadily through 2025.
- Cost of Sales
- Cost of sales increased steadily throughout the period, rising from US$904.2 million in 2021 to US$1,651.3 million in 2025. This growth suggests increasing production or procurement activity. The rate of increase appears relatively consistent, with a slight acceleration between 2023 and 2024.
- Inventories
- Inventories exhibited a consistent upward trend, increasing from US$353.1 million in 2021 to US$1,686.8 million in 2025. The growth in inventories outpaced the growth in cost of sales, particularly in the later years, contributing to the declining inventory turnover ratio. The largest absolute increase in inventory value occurred between 2023 and 2024.
The combination of rising inventory levels and increasing cost of sales, coupled with the declining inventory turnover ratio, suggests potential issues with inventory management. This could indicate overstocking, slower sales, obsolescence, or a combination of these factors. Further investigation into the reasons behind the increasing inventory and decreasing turnover is warranted.
AI Ask an analyst for more
Receivables Turnover
Vertex Pharmaceuticals Inc., receivables turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 12,001,300) | 11,020,100) | 9,869,200) | 8,930,700) | 7,574,400) | |
| Accounts receivable, net | 2,052,800) | 1,609,400) | 1,563,400) | 1,442,200) | 1,136,800) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 5.85 | 6.85 | 6.31 | 6.19 | 6.66 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.86 | 5.16 | 4.87 | 5.16 | 5.63 | |
| Amgen Inc. | 3.67 | 4.72 | 3.70 | 4.46 | 4.96 | |
| Bristol-Myers Squibb Co. | 4.87 | 5.19 | 4.93 | 5.48 | 5.65 | |
| Danaher Corp. | 6.28 | 6.75 | 6.09 | 6.40 | 6.36 | |
| Eli Lilly & Co. | 3.67 | 4.09 | 3.75 | 4.14 | 4.24 | |
| Gilead Sciences Inc. | 5.89 | 6.47 | 5.78 | 5.65 | 6.01 | |
| Johnson & Johnson | 5.48 | 5.98 | 5.73 | 5.88 | 6.14 | |
| Merck & Co. Inc. | 5.52 | 6.24 | 5.81 | 6.27 | 5.28 | |
| Pfizer Inc. | 5.27 | 5.55 | 5.33 | 9.24 | 7.16 | |
| Regeneron Pharmaceuticals Inc. | 2.50 | 2.29 | 2.31 | 2.28 | 2.66 | |
| Thermo Fisher Scientific Inc. | 5.01 | 5.23 | 5.21 | 5.53 | 4.92 | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.79 | 5.26 | 4.96 | 5.76 | 5.54 | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.58 | 7.97 | 7.66 | 8.22 | 8.00 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Revenues ÷ Accounts receivable, net
= 12,001,300 ÷ 2,052,800 = 5.85
2 Click competitor name to see calculations.
The receivables turnover ratio exhibits fluctuations over the five-year period. While generally remaining within a relatively narrow range, observable shifts warrant further consideration. Revenues demonstrate a consistent upward trajectory throughout the period, while accounts receivable also increased, though not always in direct proportion to revenue growth.
- Receivables Turnover Trend
- The receivables turnover ratio decreased from 6.66 in 2021 to 6.19 in 2022, indicating a slight lengthening in the time it takes to collect receivables. A modest recovery to 6.31 was observed in 2023. The ratio then increased to 6.85 in 2024, suggesting improved efficiency in collecting receivables. However, 2025 saw a decline to 5.85, representing the lowest value over the observed period.
The increase in accounts receivable from 2021 to 2025 is substantial, growing from US$1,136,800 thousand to US$2,052,800 thousand. Despite revenue increases, the decreasing receivables turnover in 2025 suggests a potential slowdown in the collection process or a shift in credit terms extended to customers. The 2024 increase in turnover, concurrent with rising revenue, suggests effective management of receivables during that year.
- Relationship to Revenue
- While revenues consistently increased year-over-year, the receivables turnover ratio did not follow the same pattern. The divergence in 2025, where revenue continued to grow but the turnover ratio decreased, is a key observation. This suggests that a larger proportion of sales were made on credit, or that collection efforts were less effective, requiring a greater investment in outstanding receivables to support the higher revenue level.
The fluctuations in the receivables turnover ratio, particularly the decline in the most recent year, merit further investigation. Analysis should focus on changes in credit policies, customer payment behavior, and the effectiveness of collection procedures to understand the underlying drivers of these trends.
AI Ask an analyst for more
Payables Turnover
Vertex Pharmaceuticals Inc., payables turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cost of sales | 1,651,300) | 1,530,500) | 1,262,200) | 1,080,300) | 904,200) | |
| Accounts payable | 461,700) | 413,000) | 364,900) | 303,900) | 195,000) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 3.58 | 3.71 | 3.46 | 3.55 | 4.64 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.07 | 5.74 | 5.54 | 5.94 | 6.05 | |
| Amgen Inc. | 5.09 | 6.74 | 5.32 | 4.08 | 4.72 | |
| Bristol-Myers Squibb Co. | 3.90 | 3.88 | 3.28 | 3.33 | 3.37 | |
| Danaher Corp. | 5.45 | 5.52 | 5.58 | 5.45 | 4.48 | |
| Eli Lilly & Co. | 2.05 | 2.61 | 2.73 | 3.43 | 4.38 | |
| Gilead Sciences Inc. | 8.72 | 7.50 | 11.81 | 6.25 | 9.36 | |
| Johnson & Johnson | 2.52 | 2.66 | 2.76 | 2.66 | 2.70 | |
| Merck & Co. Inc. | 3.72 | 3.72 | 4.11 | 4.08 | 2.96 | |
| Pfizer Inc. | 3.07 | 3.17 | 3.72 | 5.04 | 5.53 | |
| Regeneron Pharmaceuticals Inc. | 2.24 | 2.50 | 2.99 | 2.65 | 4.32 | |
| Thermo Fisher Scientific Inc. | 7.27 | 8.18 | 8.97 | 7.67 | 6.83 | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.72 | 4.08 | 4.25 | 4.28 | 4.23 | |
| Payables Turnover, Industry | ||||||
| Health Care | 6.15 | 6.10 | 5.97 | 5.79 | 5.84 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of sales ÷ Accounts payable
= 1,651,300 ÷ 461,700 = 3.58
2 Click competitor name to see calculations.
The accounts payable activity, as measured by payables turnover, demonstrates a generally stable pattern over the five-year period, with some fluctuation. Cost of sales consistently increased year over year, while accounts payable also exhibited an increasing trend, though at a varying rate.
- Payables Turnover Trend
- Payables turnover decreased from 4.64 in 2021 to 3.55 in 2022, representing a notable decline. It continued to decrease slightly to 3.46 in 2023, reaching its lowest point during the observed period. A modest recovery was seen in 2024, with the ratio increasing to 3.71. The most recent year, 2025, shows a slight decrease again, settling at 3.58.
- Relationship to Cost of Sales
- The initial decrease in payables turnover coincided with a substantial increase in both cost of sales and accounts payable between 2021 and 2022. While cost of sales continued to rise in subsequent years, the growth rate of accounts payable moderated, contributing to the stabilization and slight recovery of the payables turnover ratio. The increase in cost of sales from 2021 to 2025 was 82.8%, while accounts payable increased by 136.8% over the same period.
- Accounts Payable Growth
- Accounts payable increased significantly from 2021 to 2022, growing by 56.3%. Subsequent increases were more moderate, at 20.1% from 2022 to 2023, 13.5% from 2023 to 2024, and 11.7% from 2024 to 2025. This suggests a potential shift in payment terms or supplier relationships following the initial surge in 2022.
Overall, the payables turnover ratio indicates a consistent ability to manage short-term obligations relative to purchases, despite fluctuations. The observed trends suggest the company effectively managed its payment cycle, although the initial decline in turnover warrants consideration in the context of broader financial performance.
AI Ask an analyst for more
Working Capital Turnover
Vertex Pharmaceuticals Inc., working capital turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current assets | 11,201,000) | 9,596,400) | 14,144,200) | 13,234,800) | 9,560,600) | |
| Less: Current liabilities | 3,861,200) | 3,564,600) | 3,547,400) | 2,742,100) | 2,142,000) | |
| Working capital | 7,339,800) | 6,031,800) | 10,596,800) | 10,492,700) | 7,418,600) | |
| Revenues | 12,001,300) | 11,020,100) | 9,869,200) | 8,930,700) | 7,574,400) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 1.64 | 1.83 | 0.93 | 0.85 | 1.02 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 9.85 | 5.40 | 2.25 | 3.82 | 3.37 | |
| Bristol-Myers Squibb Co. | 7.83 | 7.79 | 4.60 | 8.30 | 3.95 | |
| Danaher Corp. | 4.13 | 8.85 | 4.22 | 4.20 | 8.40 | |
| Eli Lilly & Co. | 3.19 | 10.32 | — | 31.84 | 8.33 | |
| Gilead Sciences Inc. | 4.43 | 3.99 | 5.61 | 8.42 | 8.54 | |
| Johnson & Johnson | 62.88 | 15.94 | 11.81 | — | 5.95 | |
| Merck & Co. Inc. | 4.28 | 6.19 | 9.29 | 5.16 | 7.62 | |
| Pfizer Inc. | 10.58 | 8.64 | — | 11.09 | 4.83 | |
| Regeneron Pharmaceuticals Inc. | 1.05 | 0.97 | 0.82 | 0.96 | 1.59 | |
| Thermo Fisher Scientific Inc. | 3.30 | 4.87 | 4.05 | 5.46 | 5.87 | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.50 | 7.86 | 6.68 | 7.25 | 5.87 | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 11.25 | 12.35 | 10.99 | 11.30 | 8.57 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Revenues ÷ Working capital
= 12,001,300 ÷ 7,339,800 = 1.64
2 Click competitor name to see calculations.
The working capital turnover ratio exhibited fluctuating behavior over the five-year period. Initial values decreased before increasing significantly in later years. Working capital itself demonstrated an initial increase followed by a decline and subsequent partial recovery.
- Working Capital Turnover Trend
- The working capital turnover ratio began at 1.02 in 2021, decreased to 0.85 in 2022, and then rose to 0.93 in 2023. A substantial increase was observed in 2024, with the ratio reaching 1.83. This upward trend continued, albeit at a slower pace, with the ratio settling at 1.64 in 2025.
- Working Capital Trend
- Working capital increased from US$7,418,600 thousand in 2021 to US$10,492,700 thousand in 2022, representing a significant expansion. It remained relatively stable in 2023 at US$10,596,800 thousand before experiencing a considerable decrease to US$6,031,800 thousand in 2024. A partial recovery was noted in 2025, with working capital reaching US$7,339,800 thousand.
- Relationship between Turnover and Working Capital
- The decrease in the working capital turnover ratio from 2021 to 2022 coincided with an increase in working capital, suggesting a slower rate of revenue generation relative to the investment in working capital. The subsequent increase in the turnover ratio in 2024 and 2025, despite a decrease in working capital in 2024, indicates improved efficiency in utilizing working capital to generate revenue. The substantial increase in revenues in 2024 and 2025 likely contributed to this improved turnover.
The observed fluctuations suggest a dynamic relationship between the company’s operational activity, revenue generation, and management of working capital. The recent increases in the turnover ratio are a positive indicator, suggesting improved efficiency, but should be considered in conjunction with the changes in absolute working capital levels.
AI Ask an analyst for more
Average Inventory Processing Period
Vertex Pharmaceuticals Inc., average inventory processing period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 0.98 | 1.27 | 1.71 | 2.35 | 2.56 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 373 | 287 | 214 | 156 | 143 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 99 | 90 | 73 | 75 | 65 | |
| Amgen Inc. | 189 | 199 | 411 | 281 | 231 | |
| Bristol-Myers Squibb Co. | 70 | 67 | 91 | 84 | 77 | |
| Danaher Corp. | 90 | 88 | 96 | 91 | 88 | |
| Eli Lilly & Co. | 454 | 329 | 298 | 237 | 194 | |
| Gilead Sciences Inc. | 104 | 100 | 100 | 97 | 89 | |
| Johnson & Johnson | 171 | 165 | 154 | 147 | 127 | |
| Merck & Co. Inc. | 148 | 147 | 144 | 124 | 159 | |
| Pfizer Inc. | 242 | 222 | 149 | 95 | 107 | |
| Regeneron Pharmaceuticals Inc. | 556 | 572 | 519 | 562 | 292 | |
| Thermo Fisher Scientific Inc. | 75 | 72 | 72 | 79 | 94 | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 164 | 149 | 143 | 119 | 117 | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 48 | 48 | 50 | 46 | 46 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 0.98 = 373
2 Click competitor name to see calculations.
An examination of the provided financial information reveals a consistent lengthening of the average inventory processing period alongside a declining inventory turnover ratio over the five-year period. This suggests a growing inefficiency in managing inventory.
- Inventory Turnover
- The inventory turnover ratio decreased steadily from 2.56 in 2021 to 0.98 in 2025. This indicates that the company is selling its inventory at a progressively slower rate. A ratio of 0.98 suggests that, on average, inventory is almost entirely unsold after one year.
- Average Inventory Processing Period
- The average inventory processing period increased significantly from 143 days in 2021 to 373 days in 2025. This lengthening period corresponds directly with the declining inventory turnover. The increase suggests that inventory is being held for longer durations before being sold, potentially indicating issues with demand forecasting, product obsolescence, or inefficiencies in the supply chain. The substantial increase from 287 days in 2024 to 373 days in 2025 warrants particular attention.
The combined trend of decreasing inventory turnover and increasing average inventory processing period points to a potential build-up of inventory. This could tie up working capital, increase storage costs, and potentially lead to write-downs if inventory becomes obsolete. Further investigation into the reasons behind these trends is recommended.
AI Ask an analyst for more
Average Receivable Collection Period
Vertex Pharmaceuticals Inc., average receivable collection period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 5.85 | 6.85 | 6.31 | 6.19 | 6.66 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 62 | 53 | 58 | 59 | 55 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 75 | 71 | 75 | 71 | 65 | |
| Amgen Inc. | 99 | 77 | 99 | 82 | 74 | |
| Bristol-Myers Squibb Co. | 75 | 70 | 74 | 67 | 65 | |
| Danaher Corp. | 58 | 54 | 60 | 57 | 57 | |
| Eli Lilly & Co. | 99 | 89 | 97 | 88 | 86 | |
| Gilead Sciences Inc. | 62 | 56 | 63 | 65 | 61 | |
| Johnson & Johnson | 67 | 61 | 64 | 62 | 59 | |
| Merck & Co. Inc. | 66 | 58 | 63 | 58 | 69 | |
| Pfizer Inc. | 69 | 66 | 69 | 40 | 51 | |
| Regeneron Pharmaceuticals Inc. | 146 | 160 | 158 | 160 | 137 | |
| Thermo Fisher Scientific Inc. | 73 | 70 | 70 | 66 | 74 | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 76 | 69 | 74 | 63 | 66 | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 46 | 48 | 44 | 46 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.85 = 62
2 Click competitor name to see calculations.
The average receivable collection period exhibited fluctuations over the five-year period. While generally remaining within a narrow range, observable shifts indicate changes in the efficiency of collecting receivables.
- Average Receivable Collection Period
- The average receivable collection period initially increased from 55 days in 2021 to 59 days in 2022. This suggests a lengthening in the time required to collect on credit sales during that year.
- Following the increase, the period stabilized at 58 days in 2023 before decreasing to 53 days in 2024, indicating improved collection efficiency.
- However, in 2025, the average collection period rose again to 62 days, representing the longest period observed throughout the analyzed timeframe. This recent increase warrants further investigation to determine the underlying causes.
The observed changes in the average receivable collection period do not appear to correlate directly with the receivables turnover ratio. Receivables turnover decreased from 6.66 in 2021 to 5.85 in 2025, but the collection period did not consistently move in the same direction. This suggests factors beyond simply the volume of credit sales are influencing how quickly receivables are collected.
The increase in the collection period in both 2022 and 2025 could be due to a variety of factors, including changes in credit terms offered to customers, a shift in the customer mix, or potential issues with the collection process itself. The company should investigate these possibilities to optimize its working capital management.
AI Ask an analyst for more
Operating Cycle
Vertex Pharmaceuticals Inc., operating cycle calculation, comparison to benchmarks
No. days
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 373 | 287 | 214 | 156 | 143 | |
| Average receivable collection period | 62 | 53 | 58 | 59 | 55 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 435 | 340 | 272 | 215 | 198 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 174 | 161 | 148 | 146 | 130 | |
| Amgen Inc. | 288 | 276 | 510 | 363 | 305 | |
| Bristol-Myers Squibb Co. | 145 | 137 | 165 | 151 | 142 | |
| Danaher Corp. | 148 | 142 | 156 | 148 | 145 | |
| Eli Lilly & Co. | 553 | 418 | 395 | 325 | 280 | |
| Gilead Sciences Inc. | 166 | 156 | 163 | 162 | 150 | |
| Johnson & Johnson | 238 | 226 | 218 | 209 | 186 | |
| Merck & Co. Inc. | 214 | 205 | 207 | 182 | 228 | |
| Pfizer Inc. | 311 | 288 | 218 | 135 | 158 | |
| Regeneron Pharmaceuticals Inc. | 702 | 732 | 677 | 722 | 429 | |
| Thermo Fisher Scientific Inc. | 148 | 142 | 142 | 145 | 168 | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 240 | 218 | 217 | 182 | 183 | |
| Operating Cycle, Industry | ||||||
| Health Care | 96 | 94 | 98 | 90 | 92 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 373 + 62 = 435
2 Click competitor name to see calculations.
The operating cycle has exhibited a consistent lengthening trend over the five-year period. Each component contributing to the operating cycle – average inventory processing period and average receivable collection period – has demonstrated changes that collectively contribute to this overall trend.
- Average Inventory Processing Period
- The average inventory processing period has increased substantially from 143 days in 2021 to 373 days in 2025. This represents a more than 160% increase over the period. The rate of increase has also accelerated, with larger year-over-year changes observed in the later years of the period. This suggests a growing inefficiency in managing inventory, potentially indicating issues with inventory turnover, obsolescence, or production planning.
- Average Receivable Collection Period
- The average receivable collection period has shown a more moderate increase, moving from 55 days in 2021 to 62 days in 2025. While generally stable, there were fluctuations within the period, with a decrease to 53 days in 2024 before returning to 62 days in 2025. This suggests some variability in the company’s ability to collect receivables, but overall remains relatively consistent compared to the inventory processing period.
- Operating Cycle
- The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, has increased from 198 days in 2021 to 435 days in 2025. This represents an increase of over 120%. The increasing trend is primarily driven by the significant lengthening of the average inventory processing period. A longer operating cycle generally implies that the company is taking longer to convert its investments in inventory and receivables into cash, potentially impacting liquidity and requiring more working capital financing.
The combined effect of these trends indicates a growing inefficiency in the company’s short-term operating activities. The substantial increase in the inventory processing period warrants further investigation to identify the underlying causes and implement corrective measures.
AI Ask an analyst for more
Average Payables Payment Period
Vertex Pharmaceuticals Inc., average payables payment period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 3.58 | 3.71 | 3.46 | 3.55 | 4.64 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 102 | 98 | 106 | 103 | 79 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 72 | 64 | 66 | 61 | 60 | |
| Amgen Inc. | 72 | 54 | 69 | 90 | 77 | |
| Bristol-Myers Squibb Co. | 94 | 94 | 111 | 109 | 108 | |
| Danaher Corp. | 67 | 66 | 65 | 67 | 82 | |
| Eli Lilly & Co. | 178 | 140 | 134 | 106 | 83 | |
| Gilead Sciences Inc. | 42 | 49 | 31 | 58 | 39 | |
| Johnson & Johnson | 145 | 137 | 132 | 137 | 135 | |
| Merck & Co. Inc. | 98 | 98 | 89 | 89 | 123 | |
| Pfizer Inc. | 119 | 115 | 98 | 72 | 66 | |
| Regeneron Pharmaceuticals Inc. | 163 | 146 | 122 | 138 | 84 | |
| Thermo Fisher Scientific Inc. | 50 | 45 | 41 | 48 | 53 | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 98 | 90 | 86 | 85 | 86 | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 59 | 60 | 61 | 63 | 63 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.58 = 102
2 Click competitor name to see calculations.
The average payables payment period exhibited an increasing trend from 2021 to 2023, followed by a slight decrease in 2024 and a subsequent increase in 2025. This indicates a lengthening in the time taken to settle obligations to suppliers, with some fluctuation in recent periods.
- Payables Turnover
- Payables turnover decreased from 4.64 in 2021 to 3.55 in 2022, suggesting a slower rate of purchasing on credit. A further slight decrease to 3.46 was observed in 2023. The ratio experienced a modest recovery to 3.71 in 2024, but then decreased again to 3.58 in 2025. This pattern mirrors the changes observed in the average payables payment period.
- Average Payables Payment Period
- The average payables payment period increased from 79 days in 2021 to 103 days in 2022, representing a 30.4% increase. This trend continued in 2023, with the period reaching 106 days. A decrease to 98 days was noted in 2024, but the period increased again to 102 days in 2025. The period has generally remained above 100 days since 2022.
The observed increases in the average payables payment period, coupled with the declining payables turnover, suggest the company is taking longer to pay its suppliers. This could be due to a variety of factors, including negotiating extended payment terms, managing cash flow, or changes in supplier relationships. The slight decrease in 2024 may indicate a temporary shift in payment practices, but the return to an elevated period in 2025 suggests the longer payment terms are sustained.
AI Ask an analyst for more
Cash Conversion Cycle
Vertex Pharmaceuticals Inc., cash conversion cycle calculation, comparison to benchmarks
No. days
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 373 | 287 | 214 | 156 | 143 | |
| Average receivable collection period | 62 | 53 | 58 | 59 | 55 | |
| Average payables payment period | 102 | 98 | 106 | 103 | 79 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 333 | 242 | 166 | 112 | 119 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 102 | 97 | 82 | 85 | 70 | |
| Amgen Inc. | 216 | 222 | 441 | 273 | 228 | |
| Bristol-Myers Squibb Co. | 51 | 43 | 54 | 42 | 34 | |
| Danaher Corp. | 81 | 76 | 91 | 81 | 63 | |
| Eli Lilly & Co. | 375 | 278 | 261 | 219 | 197 | |
| Gilead Sciences Inc. | 124 | 107 | 132 | 104 | 111 | |
| Johnson & Johnson | 93 | 89 | 86 | 72 | 51 | |
| Merck & Co. Inc. | 116 | 107 | 118 | 93 | 105 | |
| Pfizer Inc. | 192 | 173 | 120 | 63 | 92 | |
| Regeneron Pharmaceuticals Inc. | 539 | 586 | 555 | 584 | 345 | |
| Thermo Fisher Scientific Inc. | 98 | 97 | 101 | 97 | 115 | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 142 | 128 | 131 | 97 | 97 | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 37 | 34 | 37 | 27 | 29 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 373 + 62 – 102 = 333
2 Click competitor name to see calculations.
An examination of short-term operating activity reveals notable shifts in key metrics between 2021 and 2025. The average inventory processing period, average receivable collection period, average payables payment period, and the resulting cash conversion cycle all demonstrate distinct trends over the five-year period.
- Average Inventory Processing Period
- The average inventory processing period exhibits a consistent upward trend, increasing from 143 days in 2021 to 373 days in 2025. This indicates a lengthening of the time required to convert raw materials into finished goods and ultimately sell them. The most significant increase occurred between 2023 and 2025.
- Average Receivable Collection Period
- The average receivable collection period remained relatively stable between 2021 and 2023, fluctuating between 55 and 59 days. A slight decrease to 53 days was observed in 2024, followed by an increase to 62 days in 2025. This suggests a minor fluctuation in the efficiency of collecting payments from customers.
- Average Payables Payment Period
- The average payables payment period increased from 79 days in 2021 to 103 days in 2022, then stabilized around 102-106 days for the subsequent years, decreasing slightly to 98 days in 2024. This indicates a lengthening of the time taken to pay suppliers, with a slight contraction in 2024.
- Cash Conversion Cycle
- The cash conversion cycle demonstrates a substantial upward trend, rising from 119 days in 2021 to 333 days in 2025. This increase is primarily driven by the lengthening inventory processing period, although changes in the receivable and payable periods also contribute. The most pronounced increase in the cash conversion cycle occurred between 2023 and 2025, mirroring the significant rise in the inventory processing period. A longer cash conversion cycle generally implies that the company is tying up more cash in its operations for extended periods.
In summary, the observed trends suggest a growing inefficiency in managing the flow of inventory, coupled with a moderate extension in payment terms to suppliers. The resulting increase in the cash conversion cycle warrants further investigation to determine the underlying causes and potential implications for liquidity and operational efficiency.
AI Ask an analyst for more